Novel immunomodulators for topical skin disease therapy

Bibliography

• SULZBERGER MB, WITTEN VH: The effect of topically applied compound F in selected dermatoses. J. Invest. Dermatol. (1952) 19:101–102.?
   PubMed Web of Science ®Google Scholar
• SMITH EW: Four decades of topical corticosteroid assessment. Curr. Problems in Dermatol. (1995) 22:134–141.? A nice review of topical corticosteroid use and side effects.?
   Google Scholar
• PARENTE L, SOLITO E, GIANNESSI P et al. Inhibition of? eicosanoid formation and lipocortin induction by glucocorticoids in human cell lines and in patients with inflammatory lung disease. Pharmacol Res. (1992) 26 (suppl 2):44–45.?
   Google Scholar
• HULLIN F, RAYNAL P, RAGAB-THOMAS JMF et al.: Effectof dexamethasone on prostacyclin synthesis and on lipocortin status in human endothelial cells. J. Biol. Chem. (1989) 264:3506–3511.?
   Web of Science ®Google Scholar
• BORSON DB, GRUENERT DC: Glucocorticoids induceneutral endopeptidase in transformed human tracheal epithelial cells. Am. J. Physiol. (1991) 260:L83–L90.?
   Web of Science ®Google Scholar
• SHEINMAN RI, COGSWELL PC, LOFQUIST AK et al.: Roleof transcriptional activation of IKBcc in mediation of immunosuppression by glucocorticoids. Science (1995) 270:283–286.?
   PubMed Web of Science ®Google Scholar
• AUPHAN N, DIDONATO JA, ROSETTE C et al.: Immuno-suppression by glucocorticoids: Inhibition of NFKB activity through induction of IkB synthesis. Science (1995) 270:286–289.?
   Web of Science ®Google Scholar
• LEUNG DYM, SZEFLER SJ: Diagnosis and management of steroid-resistant asthma. Clin. Chest Med. (1997) 18:611–626.?
   Web of Science ®Google Scholar
• ROBERT C, KUPPER TS: Inflammatory skin diseases, T? cells and immune surveillance. N Engl. J. Med. (1999) 341:1817–1828.? A review of inflammatory skin diseases with emphasis on the role of T-lymphocytes.?
   PubMed Web of Science ®Google Scholar
• HANIFIN JM, CHAN S: Biochemical and immunologic? mechanisms in atopic dermatitis: New targets for emerging therapies. J. Amer. Acad. Dermatol (1999) 41:72–77.? A review of atopic dermatitis which also outlines emerging therapies.?
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ: The immunologic and genetic basis of psoriasis. Arch. Dermatol (1999) 135:1104–1110.?
   PubMed Web of Science ®Google Scholar
• LEIFERMAN KM, ACKERMAN SJ, SAMPSON HA et al.: Dermal deposition of eosinophil-major basic protein in atopic dermatitis. N Engl. J. Med. (1985) 313:282–285.?
   PubMed Web of Science ®Google Scholar
• TAYLOR RS, BAADSGAARD 0, HAMMERBERG C, KOOPERKD: Hyperstimulatory CD1a+CD1b+CD36+ Langer-hans cells are responsible for increased autologous T lymphocyte reactivity to lesional epidermal cells of patients with atopic dematitis. j Immunol. (1991) 147:3794–3802.?
   PubMed Web of Science ®Google Scholar
• MUDDE GC, VAN REIJSEN FC, BOLAND GJ et al.: Allergenpresentation by epidermal Langerhans cells from patients with atopic dermatitis is mediated by IgE. Immunol. (1990) 69:335–341.?
   PubMed Web of Science ®Google Scholar
• GREWE M, WALTHER S, GYUFKO K, CZECH W, SCHOPF E, KRUTMANN J: Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J. Invest. Dermatol. (1995) 105:407–410.?
   PubMed Web of Science ®Google Scholar
• HANIFIN JM, CHAN SC, CHENG JB et al.: Type IV phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol. (1996) 107:51–56.?
   PubMed Web of Science ®Google Scholar
• BRANDRUP F, HOLM M, GRUNNET N et al.: Psoriasis inmonozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm. Venereol. (1982) 62:229–236.?
   PubMed Web of Science ®Google Scholar
• LEWIS HM, BAKER BS, BOKTH S et al.: Restricted T-cellreceptor VB gene usage in the skin of patients with guttate and chronic plaque psoriasis. Br. J. Dermatol (1993) 129:514–520.?
   PubMed Web of Science ®Google Scholar
• LEUNG DYM, TRAVERS JB, GIORNO R et al.: Evidence fora streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest. (1995) 96:2106–2112.?
   PubMed Web of Science ®Google Scholar
• KRUEGER JG, KRANE JF, CARTER DM, GOTTLIEB AB: Roleof growth factors, cytokines and their receptors in psoriasis. J. Invest. Dermatol. (1990) 94:135–140.?
   Google Scholar
• STRANGE P, COOPER KD, HANSEN ER et al.:T-lymphocyte clones initiated from lesional psoraitic skin release growth factors that induce keratinocyte proliferation. J. Invest. Dermatol. (1993) 101:695–700.?
   PubMed Web of Science ®Google Scholar
• ELLIS CN, GORSULOWSKY DC, HAMILTON TA et al.: Cyclosporine improves psoriasis in a double-blind study. J. Am. Med. Assoc. (1986) 256:3110–3116.?
   Web of Science ®Google Scholar
• GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al:Response of psoriasis to a lymphocyte-selective toxin (DAB38911-2) suggests a primary immune, but not a keratinocyte, pathogenic basis. Nature Med. (1995) 1:442–447.?
   PubMed Web of Science ®Google Scholar
• WRONE-SMITH T, NICKOLOFF BJ: Dermal injection ofimmunocytes induces psoriasis. J. Clin. Invest. (1996) 98:1878–1887.?
   PubMed Web of Science ®Google Scholar
• BOEHNCKE WH, DRESSEL D, ZOLLNER TM, KAUFMANNR: Pulling the trigger on psoriasis. Nature (1996) 379:777.?
   PubMedGoogle Scholar
• NICKOLOFF BJ: Animal models of psoriasis. Exp. Opin. Invest. Drugs (1999) 8(4):393–401.?
   PubMedGoogle Scholar
• REYNOLDS NJ VOORHEES, JJ, FISHER GJ: Cyclosporine A inhibits 12-0-tetradecanoyl-phorbol-13-acetate-induced cutaneous inflammation in severe combined immunodeficient mice that lack functional lympho-cytes. Br. J. Dermatol. (1998) 139:16–22.?
   PubMed Web of Science ®Google Scholar
• SCHREIBER SL: Immunophilin-sensitive protein phosphatase in cell signaling pathways. Cell (1992) 70:365–368.?
   PubMed Web of Science ®Google Scholar
• BURKE JF, PIRSCH JD, RAMOS EL et al.: Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl. J. Med. (1994) 331:358–363.?
   PubMed Web of Science ®Google Scholar
• DE RIE MA, MEINARDI MM, BOS JD: Lack of efficacy of topical cyclosporine on atopic dermatitis and allergic contact dermatitis. Acta Derm. Venereol. (1991) 71:452–454.?
   PubMed Web of Science ®Google Scholar
• DE PROST Y, BODEMER C, TEILLAC D: Double-blindrandomized placebo-controlled trial of local cyclosporine in atopic dermatitis. Acta Dermatol. (1989) 125:570.?
   Google Scholar
• EISEN D, ELLIS CN, DUELL E et al.: Effect of topical cyclosporine rinse on oral lichen planus. N Engl. J. Med. (1990) 323:290–294.?
   PubMed Web of Science ®Google Scholar
• TRAN HS, MALLI D, CHRZANOWSKI FA et al.: Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate. J. Surg. Res. (1999) 83:136–140.?
   PubMed Web of Science ®Google Scholar
• SIGAL NH, DUMONT FJ: Cyclosporine A, FK506 and rapamycin: pharmacological probes of lymphocyte signal transduction. Ann. Rev. Immunol (1992) 10:519–546.?
   Web of Science ®Google Scholar
• WAGNER R, RHOADES TA, OR YS et al.: 2-Ascomycinyloxyacetic acid derived immunosup-pressants. Independence of immunophilin binding and immunosuppressive potency. J. Med. Chem. (1998) 41:1764–1776.?
   Google Scholar
• PAUL C, HO VC: Ascomycins in dermatology. Semin.Cut. Med. Surg. (1998) 17:256–259.?
   PubMed Web of Science ®Google Scholar
• NAKAGAWA H, ETOH T, ISHIBASHI Y et al.: Tacrolimusointment for atopic dermatitis. Lancet (1994) 344:883.? First report of the successful use of topical tacrolimus in humans?
   PubMed Web of Science ®Google Scholar
• AOYAMA H, TABATA N, TANAKA M, UESUGI Y, TAGAMI H: Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% tacrolimus ointment. Br. J. Dermatol. (1995) 133:494–496.?
   PubMed Web of Science ®Google Scholar
• RUZICKA T, BIEBER T, SCHOPF E et al: A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl. J. Med. (1997) 337:816–821.?
   PubMed Web of Science ®Google Scholar
• ALAITI S, KANG S, FIEDLER VC etal.: Tacrolimus (FK506) ointment for atopic dermatitis: a Phase I study in adults and children. J. Am. Acad. Dermatol. (1998) 38:69–76.?
   Google Scholar
• BOGUNIEWICZ M, FIEDLER VC, RAIMER S et al.: A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J. Allergy Clin. Immunol (1998) 102:637–644.?
   PubMed Web of Science ®Google Scholar
• KAWASHIMA M, NAKAGAWA H, OHTSUKI M, TAMAKI K, ISHIBASHI Y: Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet (1996) 348:1240–1241.?
   PubMed Web of Science ®Google Scholar
• BIEBER T: Topical tacrolimus (FK506): a new milestone in the management of atopic dermatitis. J. Allergy Clin. Immunol. (1998) 102:555–557.?
   PubMed Web of Science ®Google Scholar
• REITAMO S, RISSANEN J, REMITZ A et al.: Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J. Invest. Dermatol (1998) 111:396–398.?
   PubMed Web of Science ®Google Scholar
• ZONNEVELD IM, RUBINS A, JABLONSKA S et al.: Topical tacrolimus is not effective in chronic plaque psoriasis. Arch. Dermatol. (1998) 134:1101–1102.?
   PubMed Web of Science ®Google Scholar
• REMITZ A, REITAMO S, ERKKO P et al.: A microplaque assay-based, double-blind trial to compare the efficacy of two tacrolimus ointment formulations with two active and two negative controls in patients with chronic plaque-type psoriasis vulgaris. Br. J. Dermatol (1996) 135:833.?
   Google Scholar
• MEINGASSNER JG, STUTZ, A: Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J. Invest. Dermatol. (1992) 98:851–855.?
   PubMed Web of Science ®Google Scholar
• MEINGASSNER JG, GRASSBERGER M, FAHRNGRUBER H et al.: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases. In vivo pharmacology. Br. J. Dermatol (1997) 137:568–576.?
   PubMed Web of Science ®Google Scholar
• RAPPERSBERGER K, MEINGASSNER JG, FIALLA R et al.: Clearing of psoriasis by a novel immunosuppressive macrolide. J. Invest. Dermatol. (1996) 106:701–710.?
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, GRAEBER M, BRAUTIGAN M et al.: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. Dermatol. (1998) 139:992–996.?
   PubMed Web of Science ®Google Scholar
• VAN LEENT EJM, GRABER M, THURSTON M, WAGENAAR A, SPULS PI, BOS JD: Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch. Dermatol. (1998) 134:805–809.?
   PubMed Web of Science ®Google Scholar
• HATANAKA H, KINO T, MIYATA S: FR-900520 and FR-900523, novel immunosuppressants isolated from? A. streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. J. Antibiotics (1988) XLI:1592–1601.?
   Google Scholar
• MOLLISON KW, FEY TA, GAUVIN DM et al.: Discovery of ascomycin analogues with potent topical but weak systemic activity for the treatment of inflammatory skin diseases. Curr. Pharmacol Design (1998) 4:367–381.?
   Web of Science ®Google Scholar
• MOLLISON K, FEY TA, GAUVIN DM et al.: A macrolactam inhibitor of T helper Type 1 and T helper Type 2 cytokine biosynthesis for topical treatment of inflam-matory skin diseases. J. Invest. Dermatol. (1999) 112:729–738.?
   PubMed Web of Science ®Google Scholar
• JUNE CH, LEDBETTER JA, GILLESPIE MM, LINDSTROM T,LINDSTROM CB: T cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin-2 gene expression. Mol. Cell. Biol. (1987) 7:4472–4480.?
   Web of Science ®Google Scholar
• SHIMIZU T, MUTOH H: Structure and regulation of platelet-activating factor receptor gene. In: Eicosanoids, and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury 3, Honn (Ed.) Plenum Press, New York (1997):197–204.?
   Google Scholar
• BRAIN SD, WILLIAMS TJ: Leukotrienes and inflamma-tion. Pharmac. Ther. (1990) 46:57–66.?
   PubMedGoogle Scholar
• SERHAN CN, HAEGGSTROM JZ, LESLIE CC: Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J (1996) 10:1147–1158.?
   PubMed Web of Science ®Google Scholar
• SHIMIZU T: The future potential of eicosanoids and their inhibitors in paediatric practice. Drugs (1998) 56:169–176.?
   PubMed Web of Science ®Google Scholar
• DENNIS EA: Phospholipase A2. Trends Biochem. Sci.(1997) 22:1–2.?
   Google Scholar
• WILLIAMS CW, DUBOIS RN: Prostaglandin endoper-oxide synthase: why two isoforms? Am. J. Physic)]. (1996) 270:G393–400.?
   PubMed Web of Science ®Google Scholar
• LANGENBACH R, MORHAM SG, LOFTIN CD et al: Prosta-glandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell (1995) 83:483–490.?
   Web of Science ®Google Scholar
• MORHAM SG, LANGENBACH R, LOFTIN CD et al: Prosta-glandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell (1995) 83:472–482.?
   Google Scholar
• CAMP RDR, GREAVES MW: Inflammatory mediators in the skin. Br. Med. Bull. (1987) 43:401–414.?
   PubMed Web of Science ®Google Scholar
• STANDIFORD TJ, KUNKEL SL, ROLFE MW et al: Regula-tion of alveolar macrophage- and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am. J. Respir. Cell Mol. Biol. (1992) 6:75–83.?
   Web of Science ®Google Scholar
• WOODWARD DF, HAWLEY SB, WILLIAMS LS et al: Studies on the ocular pharmacology of PGD2. Invest. Ophthalm. Vis. Sci. (1990) 31:138–146.?
   PubMed Web of Science ®Google Scholar
• GREAVES MW, CAMP RDR: Prostaglandins, leukotrie-nes, phospholipase, platelet-activating factor and cytokines: an integrated approach to inflammation of? human skin. Arch. Dermatol. Res. (1988) 280 (Suppl.):33–41.?
   Google Scholar
• GRAHAME R: Transdermal non-steroidal anti-inflammatory agents. Br. J. Clin. Pharmacol (1995) 49:32–36.?
   Google Scholar
• BROOKS RR, BONK KR, DECKER GE, MILLER KE: Anti-inflammatory activity of orpanoxin administered orally and topically to rodents. Agents Actions (1985) 16:369–376.?
   PubMedGoogle Scholar
• SNYDER DS, EAGLSTEIN WH: Topical indomethacin and sunburn. Br. J. Dermatol (1974) 90:91–93.?
   PubMed Web of Science ®Google Scholar
• IBBOTSON SH, DIFFEY BL, FARR PM: The effect of topical indomethacinon ultraviolet-radiation-induced erythema. Br. J. Dermatol (1996) 135:523–527.?
   PubMed Web of Science ®Google Scholar
• BUCKMAN SY, GRESHAM A, HALE P et al.: COX-2 expres-sion is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis (1998) 19:723–729.?
   PubMed Web of Science ®Google Scholar
• MAYATEPEK E, HOFFMAN GF: Leukotrienes: Biosyn-thesis, metabolism and pathophysiological signifi-cance. Ped. Res. (1994) 37:1–9.?
   Google Scholar
• CAMP RDR, RUSSELL JONES R, BRAIN SD, WOOLLARD PM, GREAVES MW: Production of intraepidermal microab-scesses by topical application of leukotriene B4. J. Invest. Dermatol. (1984) 82:202–204.?
   PubMed Web of Science ®Google Scholar
• CAMP RDR, COUTTS AA, GREAVES MW, KAY AB, WALPORT MJ: Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4. Br. J. Pharmacol. (1986) 88:394.?
   Google Scholar
• JOHNSON EN, SUN D, CHEN X-S, FUNK CD: Lipoxyge-nase gene disruption studies: status and applications. Adv. Exp. Med. Biol. (1998):63–73.?
   Google Scholar
• CARUCCI JA, WASHENIK K, WEINSTEIN A, SHUPACK J, COHEN DE: The leukotriene antagonist zifurlukast as a therapeutic agent for atopic dermatitis. Arch. Dermatol (1998) 134:785–786.?
   PubMed Web of Science ®Google Scholar
• MARLEAU S, FRUTEAU DE LACLOS B, SANCHEZ AB, POUBELLE PE, BORGEAT P: Role of 5-lipoxygenase products in the local accumulation of neutrophils in dermal inflammation in the rabbit. J. Immunol (1999) 163:3449–3458.?
   PubMed Web of Science ®Google Scholar
• PINCKARD RN, WOODARD DS, SHOWELL HJ et al.: Structural and (path()) physiological activity of platelet-activating factor. Clin. Rev. Allergy (1994) 13:329–339.?
   Google Scholar
• MALLET Al, CUNNINGHAM FM: Structural identification of platelet-activating factor in psoriatic scale. Biochem. Biophys. Res. Commun. (1985) 126:192–199.?
   Web of Science ®Google Scholar
• TRAVERS JB, MURPHY RC, JOHNSON CA et al.: Identifica-tion and pharmacological characterization of platelet-activating factor and related 1-palmitoyl species in human inflammatory blistering diseases. Prostaglandins (1998) 56:305–324.?
   Web of Science ®Google Scholar
• MARKEY AC, BARKER JN, ARCHER CB et al.: Platelet-activating factor-induced clinical and histopa-thological responses in atopic skin and their? © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3)? modulation by the PAF antagonist BN 52063. J. Amer. Acad. Dermatol. (1990) 23:263–268.?
   Google Scholar
• MICHEL L, DENIZOT Y, THOMAS Y et al.: Production of PAF-acether by human epidermal cells. J. Invest. Dermatol. (1990) 95:576–581.?
   PubMed Web of Science ®Google Scholar
• TRAVERS JB, HUFF JC, ROLA-PLESZCYNSKI M, GELFAND EW, MORELLI JG, MURPHY RC: Identification of functional platelet-activating factor receptors on human keratinocytes. J. Invest. Dermatol. (1995) 105:816–823.?
   PubMed Web of Science ®Google Scholar
• PEI Y, BARBER LA, MURPHY RC et al: Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. J. Immunol. (1998) 161:1954–1961.?
   PubMed Web of Science ®Google Scholar
• SUMMERS JB, ALBERT DH: Platelet-activating factor antagonists. Adv. Pharmacol (1995) 32:67–168.?
   PubMedGoogle Scholar
• HELLEWELL PG, WILLIAMS TJ: Antagonism of platelet-activating factor-induced oedema formation in rabbit skin: a comparison of different antagonists. Br. J. Pharmacol. (1989) 97:171–180.?
   PubMed Web of Science ®Google Scholar
• TRAVERS JB, PEI Y, MORIN SM, HOOD AF: Anti-inflammatory activity of the paltelet-activating factor receptor antagonist A-85783. Arch. Dermatol. Res. (1998) 290:569–573.?
   PubMed Web of Science ®Google Scholar
• ISHII S, KUWAKI T, NAGASE T et al: Impaired anaphy-lactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med. (1998) 187:1779–1788.?
   PubMed Web of Science ®Google Scholar
• ISHII S, NAGASE T, TASHIRO F et al.: Bronchial hyperre-activity, increased endotoxin lethality and melanocyte tumorigenesis in transgenic mouse overexpressing platelet-activating factor receptors. EMBO (1997) 16:133–142.?
   PubMed Web of Science ®Google Scholar
• STAFFORINI DM, MCINTYRE TM, ZIMMERMAN GA, PRESCOTT SM: Platelet-activating factor acetylhydro-lases. J. Biol. Chem. (1977) 272:17895–17898.?
   Google Scholar
• ZIMMERMAN GA, MCINTYRE TM, MEHRA M, PRESCOTTSM: Endothelial cell-associated platelet-activating factor: a novel mechanism for signal intracellular adhesion. J. Cell. Biol. (1990) 110:529–540.?
   PubMedGoogle Scholar
• MURPHY RC Free radical-induced oxidation of? glycerophosphocholine lipids and formation of? biologically active products. Adv. Exp. Med. Biol. (1996) 416:51–58.?
   PubMedGoogle Scholar
• MARATHE GK, DAVIES SS, HARRISON KA et al.: Inflam-? matory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J. Biol. Chem. (1999) 274:28395–28404.?
   PubMed Web of Science ®Google Scholar
• GIJON MA, LESLIE CC: The regulation of artachidonic acid release and cytosolic phospholipase A2 activa-tion. J. Leuk. Biol. (1999) 65:330–336.?
   PubMed Web of Science ®Google Scholar
• UOZUMI N, KUME K, NAGASE T et al.: Role of cytosolic phospholipase A2 in allergic response and parturi-tion. Nature (1997) 390:618–622.? Demonstrates using a cPLA2 knockout mouse the non-redundancy of cPLA2 in allergic responses.?
   PubMed Web of Science ®Google Scholar
• BONVENTRE JV, HUANG Z, TAHERI MR et al.: Reduced? fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature (1997) 390:622–626.?
   Web of Science ®Google Scholar
• GRASS DS, FELKNER RH, CHIANG M-Y et al.: Expressionof human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J. Clin. Invest. (1996) 97:2233–2241.?
   PubMed Web of Science ®Google Scholar
• TRAMPOSCH KM, CHILTON FH, STANLEY PL et al.: Inhibitor of phospholipase A2 blocks eicosanoid and platelet-activating factor biosynthesis and has topical anti-inflammatory activity. J. Pharmacol. Exp. Therapeut. (1994) 271:852–859.?
   PubMed Web of Science ®Google Scholar
• SNYDER DW, BACH NJ, DILLARD RD et al.: Pharmacology of LY315920/S-5920, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs, SPI. J. Pharmacol Exp. Therapeut. (1999) 288:1117–1124.?
   PubMed Web of Science ®Google Scholar
• MURAKAMI M, SHIMBARA S, KAMBE T et al.: The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release. J. Biol. Chem. (1998) 273:14411–14423.?
   PubMed Web of Science ®Google Scholar